Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glo-BNHL
2024-510575-38-00Phase 3Authorised
- Sponsor
- University of Birmingham
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label trial of odronextamab and loncastuximab tesirine in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 2 more (2 arms), sponsored by University of Birmingham. Primary endpoints: Objective response after 12 weeks and Complete response within up to 3 cycles. Planned start Aug 2025; status: authorised.
02
Drugs
odronextamabloncastuximab tesirine
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2024-510575-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510575-38-00.